1
|
Fernandes-Siqueira LO, Melo RRA, Wermelinger LS, Almeida FCL, Salmon D, Ferreira GC, DA Poian AT. An institutional COVID-19 initiative: creation of a biobank and serological data analysis in pre- and post-vaccination cohorts. AN ACAD BRAS CIENC 2025; 97:e20240819. [PMID: 40136202 DOI: 10.1590/0001-3765202520240819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2024] [Accepted: 12/17/2024] [Indexed: 03/27/2025] Open
Abstract
The COVID-19 pandemic has left a legacy in the management of health emergencies, but sentinel surveillance was relatively underused, despite its significant role in decision-making during epidemics. Here we describe a sentinel surveillance for anti-SARS-CoV-2 serology carried out on a cohort of 395 individuals at a Brazilian institution, from October 2020 to December 2022. A total of 1,507 serum samples were analyzed for IgG and IgA against SARS-CoV-2 Spike (S) or nucleocapsid (N) proteins, in the pre- and post-vaccination periods. The latter included two doses of CoronaVac (group 1, G1), or ChAdOx-1 or BNT162b2 (group 2, G2), followed by heterologous booster doses. In the pre-vaccination phase, 26.5% of the participants showed IgG reactivity for S and 13.7% for N. After the vaccines' first dose, S IgG response was positive in 66.6% or 98% of G1 or G2 participants, respectively, whereas 100% of the participants showed S IgG positivity after the second dose, and S IgG and IgA after the booster. This initiative enabled the examination of viral transmission beyond hospital environments, which has rarely been explored, and established protocols for managing future emergencies. In addition, a serum bank and a comprehensive database are now available to the scientific community.
Collapse
Affiliation(s)
- Lorena O Fernandes-Siqueira
- Universidade Federal do Rio de Janeiro, Centro de Ciências da Saúde (CCS), Instituto de Bioquímica Médica Leopoldo de Meis, Avenida Carlos Chagas Filho, 373, Bloco K, Cidade Universitária, Ilha do Fundão, 21941-902 Rio de Janeiro, RJ, Brazil
| | - Raphael R A Melo
- Universidade Federal do Rio de Janeiro, Centro de Ciências da Saúde (CCS), Instituto de Bioquímica Médica Leopoldo de Meis, Avenida Carlos Chagas Filho, 373, Bloco K, Cidade Universitária, Ilha do Fundão, 21941-902 Rio de Janeiro, RJ, Brazil
| | - Luciana S Wermelinger
- Universidade Federal do Rio de Janeiro, Centro de Ciências da Saúde (CCS), Faculdade de Farmácia, Avenida Carlos Chagas Filho, 373, Bloco A, Cidade Universitária, Ilha do Fundão, 21941-170 Rio de Janeiro, RJ, Brazil
| | - Fabio C L Almeida
- Universidade Federal do Rio de Janeiro, Centro de Ciências da Saúde (CCS), Instituto de Bioquímica Médica Leopoldo de Meis, Avenida Carlos Chagas Filho, 373, Bloco K, Cidade Universitária, Ilha do Fundão, 21941-902 Rio de Janeiro, RJ, Brazil
| | - Didier Salmon
- Universidade Federal do Rio de Janeiro, Centro de Ciências da Saúde (CCS), Instituto de Bioquímica Médica Leopoldo de Meis, Avenida Carlos Chagas Filho, 373, Bloco K, Cidade Universitária, Ilha do Fundão, 21941-902 Rio de Janeiro, RJ, Brazil
| | - Gustavo C Ferreira
- Universidade Federal do Rio de Janeiro, Centro de Ciências da Saúde (CCS), Instituto de Bioquímica Médica Leopoldo de Meis, Avenida Carlos Chagas Filho, 373, Bloco K, Cidade Universitária, Ilha do Fundão, 21941-902 Rio de Janeiro, RJ, Brazil
| | - Andrea T DA Poian
- Universidade Federal do Rio de Janeiro, Centro de Ciências da Saúde (CCS), Instituto de Bioquímica Médica Leopoldo de Meis, Avenida Carlos Chagas Filho, 373, Bloco K, Cidade Universitária, Ilha do Fundão, 21941-902 Rio de Janeiro, RJ, Brazil
| |
Collapse
|
2
|
SARS-CoV-2 Genomic Surveillance in Brazil: A Systematic Review with Scientometric Analysis. Viruses 2022; 14:v14122715. [PMID: 36560720 PMCID: PMC9784312 DOI: 10.3390/v14122715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2022] [Revised: 11/30/2022] [Accepted: 12/02/2022] [Indexed: 12/09/2022] Open
Abstract
Several studies have monitored the SARS-CoV-2 variants in Brazil throughout the pandemic. Here, we systematically reviewed and conducted a scientometric analysis of the SARS-CoV-2 genomic surveillance studies using Brazilian samples. A Pubmed database search on October 2022 returned 492 articles, of which 106 were included. Ninety-six different strains were reported, with variant of concern (VOC) gamma (n = 35,398), VOC delta (n = 15,780), and the variant of interest zeta (n = 1983) being the most common. The top three states with the most samples in the published articles were São Paulo, Rio de Janeiro, and Minas Gerais. Whereas the first year of the pandemic presented primary circulation of B.1.1.28 and B.1.1.33 variants, consecutive replacements were observed between them and VOI zeta, VOC gamma, VOC delta, and VOC omicron. VOI mu, VOI lambda, VOC alpha, and VOC beta were also detected but failed to reach significant circulation. Co-infection, re-infection, and vaccine breakthrough reports were found. Article co-citation differed from the co-authorship structure. Despite the limitations, we expect to give an overview of Brazil's genomic surveillance studies and contribute to future research execution.
Collapse
|
3
|
Gesto JSM, Cabanelas A, Farjun B, dos Santos MC, Fidalgo-Neto AA, Kuriyama SN, Souza TML. Implemented occupational health surveillance limits the spread of SARS-CoV-2 Omicron at the workplace. Front Med (Lausanne) 2022; 9:910176. [PMID: 36111122 PMCID: PMC9468326 DOI: 10.3389/fmed.2022.910176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2022] [Accepted: 08/11/2022] [Indexed: 11/23/2022] Open
Abstract
The global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has put an enormous pressure on human societies, at both health and economic levels. Early diagnosis of SARS-CoV-2, the causative agent of 2019 coronavirus disease (COVID-19), has proved an efficient method to rapidly isolate positive individuals and reduce transmission rates, thus alleviating its negative impact on society’s well-being and economic growth. In this work, through a coordinated and centralized effort to monitor SARS-CoV-2 circulation in companies from the State of Rio de Janeiro, Brazil, we have detected and linked an early rise of infection rates in January 2022 to the introduction of the Omicron variant of concern (VoC) (BA.1). Interestingly, when the Omicron genomic isolates were compared to correlates from public datasets, it was revealed that introduction events were multiple, with possible migration routes mapping to: Mali; Oman and United States; and Italy, Latin America, and United States. In addition, we have built a haplotype network with our genomic dataset and found no strong evidence of transmission chains, between and within companies. Considering Omicron’s particularly high transmissibility, and that most of our samples (>87%) arose from 3 out of 10 companies, these findings suggest that workers from such environments were exposed to SARS-CoV-2 outside their company boundaries. Thus, using a mixed strategy in which quick molecular diagnosis finds support in comprehensive genomic analysis, we have shown that a successfully implemented occupational health program should contribute to document emerging VoC and to limit the spread of SARS-CoV-2 at the workplace.
Collapse
Affiliation(s)
- João Silveira Moledo Gesto
- SESI Innovation Center for Occupational Health, Rio de Janeiro, Brazil
- Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
- Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil
| | - Adriana Cabanelas
- SESI Innovation Center for Occupational Health, Rio de Janeiro, Brazil
| | - Bruna Farjun
- SESI Innovation Center for Occupational Health, Rio de Janeiro, Brazil
| | | | | | - Sergio N. Kuriyama
- SESI Innovation Center for Occupational Health, Rio de Janeiro, Brazil
- SENAI Innovation Institute for Green Chemistry, Rio de Janeiro, Brazil
- *Correspondence: Sergio N. Kuriyama,
| | - Thiago Moreno L. Souza
- SESI Innovation Center for Occupational Health, Rio de Janeiro, Brazil
- Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
- Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil
- National Institute of Science and Technology for Innovation on Diseases of Neglected Populations (INCT/IDN), Rio de Janeiro, Brazil
- Thiago Moreno L. Souza,
| |
Collapse
|
4
|
Kuriyama SN, Farjun B, Henriques-Santos BM, Cabanelas A, Abrantes JL, Gesto J, Fidalgo-Neto AA, Souza TML. SARS-CoV-2 Molecular Epidemiology Can Be Enhanced by Occupational Health: The Experience of Monitoring Variants of Concern in Workplaces in Rio de Janeiro, Brazil. Front Med (Lausanne) 2022; 9:862284. [PMID: 35572963 PMCID: PMC9101942 DOI: 10.3389/fmed.2022.862284] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2022] [Accepted: 04/12/2022] [Indexed: 11/13/2022] Open
Abstract
The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to extra caution in workplaces to avoid the coronavirus disease 2019 (COVID-19). In the occupational environment, SARS-CoV-2 testing is a powerful approach in providing valuable information to detect, monitor, and mitigate the spread of the virus and preserve productivity. Here a centralized Occupational Health Center provided molecular diagnosis and genomic sequences for companies and industries in Rio de Janeiro, Brazil. From May to August 2021, around 20% of the SARS-CoV-2 positive nasopharyngeal swabs from routinely tested workers were sequenced and reproduced the replacement of Gamma with Delta variant observed in regular surveillance programs. Moreover, as a proof-of-concept on the sensibility of the occupational health genomic surveillance program described here, it was also found: i) the primo-identification of B.1.139 and A.2.5 viral genomes in Brazil and ii) an improved dating of Delta VoC evolution, by identifying earlier cases associated with AY-related genomes. We interpret that SARS-CoV-2 molecular testing of workers, independent of symptom presentation, provides an earlier opportunity to identify variants. Thus, considering the continuous monitoring of SARS-CoV-2 in workplaces, positive samples from occupation health programs should be regarded as essential to improve the knowledge on virus genetic diversity and VoC emergence.
Collapse
Affiliation(s)
- Sergio N. Kuriyama
- SESI Innovation Center for Occupational Health, Rio de Janeiro, Brazil
- SENAI Innovation Institute for Green Chemistry, Rio de Janeiro, Brazil
| | - Bruna Farjun
- SESI Innovation Center for Occupational Health, Rio de Janeiro, Brazil
- SENAI Innovation Institute for Green Chemistry, Rio de Janeiro, Brazil
| | - Bianca Monteiro Henriques-Santos
- SESI Innovation Center for Occupational Health, Rio de Janeiro, Brazil
- SENAI Innovation Institute for Green Chemistry, Rio de Janeiro, Brazil
| | - Adriana Cabanelas
- SESI Innovation Center for Occupational Health, Rio de Janeiro, Brazil
- SENAI Innovation Institute for Green Chemistry, Rio de Janeiro, Brazil
| | | | - João Gesto
- Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | | | - Thiago Moreno L. Souza
- SESI Innovation Center for Occupational Health, Rio de Janeiro, Brazil
- Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
- National Institute for Science and Technology for Innovation on Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil
| |
Collapse
|